Noxxon Pharma, a Germany-based drug developer focused on blood and inflammatory diseases, has raised an extra €2m in its series D round, having initially closed it in May at €33m ($46m).
The extra money came from US-based venture capital firm CD Ventures.
In May, Dow Venture Capital, the corporate venturing unit of US-based Dow Chemical Company, reinvested in Noxxon’s fourth round led by NGN Capital as a new investor. NGN’s VC and German state-backed peers, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, FCP Op Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt and Dieckell Group, reinvested in Noxxon alongside Dow.
In aggregate, Noxxon has raised €112m after closing a €37m series C round in May 2007 on top of €40m since its launch in 1997, according to news provider Dow Jones VentureWire.
The latest investment will continue Noxxon’s drug trials in diabetes, cancer and blood conditions using its registered discovery platform, Spiegelmers.